Table 3.
Incremental Effect of Incorporating Ceramide Ratios on Model Discrimination
| Predictors in Model | Incident CHD | Incident HF | All‐Cause Mortalitya | CVD Mortalitya | Non‐CVD Mortalitya |
|---|---|---|---|---|---|
| FHS samples | |||||
| SRFsb | 0.703 | 0.841 | 0.756 | 0.834 | 0.743 |
| SRF+C22:0/C16:0 ceramide ratio | 0.716 | 0.844 | 0.780c | 0.837 | 0.771c |
| SRF+C24:0/C16:0 ceramide ratio | 0.714 | 0.844 | 0.776c | 0.832 | 0.768c |
| SHIP samples | |||||
| SRFsb | 0.7163 | 0.6691 | 0.8706 | 0.9181 | 0.8537 |
| SRF+C22:0/C16:0 ceramide ratio | 0.7165 | 0.6697 | 0.8754 | 0.9205 | 0.8590 |
| SRF+C24:0/C16:0 ceramide ratio | 0.7216 | 0.6710 | 0.8768c | 0.9224 | 0.8607 |
Data are given as C‐statistics. CHD indicates coronary heart disease; CVD, cardiovascular disease; FHS, Framingham Heart Study; HF, heart failure; SHIP, Study of Health in Pomerania; SRF, standard risk factor.
a
Prevalent CVD added to SRFs.
b
Standard risk factors: age, sex, body mass index, systolic blood pressure, antihypertensive medication, current smoking status, diabetes mellitus, total/high‐density lipoprotein cholesterol, triglycerides, and lipid‐lowering medication.
c
Confidence interval for change in C‐statistic excludes 0.